Comparative Pharmacology
Head-to-head clinical analysis: EXELDERM versus EXSEL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXELDERM versus EXSEL.
EXELDERM vs EXSEL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topical antimycotic that inhibits fungal squalene epoxidase, leading to accumulation of squalene and disruption of fungal cell wall synthesis.
Exsel (selenium sulfide) is an antifungal agent that reduces the production of cutaneous oils and exerts cytostatic effects on epidermal cells. It inhibits the growth of Pityrosporum ovale and other fungi by interfering with oxidative enzyme systems, leading to decreased sebum production and normalization of epidermal turnover.
Apply a thin layer to affected skin twice daily (morning and evening).
1-2 mg orally once daily; maximum dose 2 mg/day.
None Documented
None Documented
Not applicable due to negligible systemic absorption; after topical application, half-life in skin is several hours.
Terminal half-life: 12-18 hours (mean 15 h); requires dose adjustment in renal impairment (CrCl <30 mL/min).
Systemic absorption is minimal; any absorbed sulconazole is primarily metabolized in the liver and excreted in feces via bile; renal excretion of unchanged drug is negligible.
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites.
Category C
Category C
Topical Antifungal
Topical Antifungal